^
    1d
    Fixed-duration ibrutinib-venetoclax with MRD-guided ibrutinib-obinutuzumab intensification in first-line chronic lymphocytic leukaemia (HOVON 158/NEXT STEP): primary analysis of a multicentre, open-label, phase 2 trial. (PubMed, Lancet Haematol)
    An intensification strategy guided by response and MRD deepened remissions in individuals with residual disease and spared early responders further treatment. This approach merits further study as an alternative to fixed-duration triplet therapy.
    P2 data • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Imbruvica (ibrutinib) • Gazyva (obinutuzumab)
    1d
    STAIR: STop and Restart Acalabrutinib In fRail Patients With Previously Untreated Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=160, Active, not recruiting, French Innovative Leukemia Organisation | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2026 --> Aug 2025
    Enrollment closed • Trial primary completion date
    |
    TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus)
    |
    TP53 mutation • IGH mutation
    |
    Calquence (acalabrutinib)
    2d
    FOLLOW: French Observational Study of Patients With Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma in Real-World Settings (clinicaltrials.gov)
    P=N/A, N=1000, Active, not recruiting, French Innovative Leukemia Organisation | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> Apr 2025
    Enrollment closed • Trial primary completion date • Real-world evidence
    |
    BCL2 (B-cell CLL/lymphoma 2)
    2d
    The Evolving Therapeutic Landscape of Richter Transformation. (PubMed, Curr Hematol Malig Rep)
    The combination of the B-cell lymphoma 2 inhibitor venetoclax with CIT has emerged as a new first-line benchmark with promising response rates and overall survival...Pirtobrutinib has demonstrated responses even in heavily pretreated patients...For R/R disease, novel BTK inhibitors, bispecific antibodies, and cellular therapies are demonstrating substantial efficacy. Ongoing trials investigating combinations of these agents are poised to further transform RT management.
    Review • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Jaypirca (pirtobrutinib)
    2d
    Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. (PubMed, Front Immunol)
    Despite containing SLL deposits, the harvested melanoma produced a CD8+ T cell-predominant tumor-reactive TIL infusion product containing stem-like CD39negCD69neg CD8+ T cells. A strong overlap (60%) in the TCRβ sequences between this infusion product and peripheral blood mononuclear cells collected at the 9-month follow-up visit was evidence of long-term persistence of TIL in this patient.
    Journal • Tumor-infiltrating lymphocyte
    |
    CD8 (cluster of differentiation 8) • CD69 (CD69 Molecule) • IL2 (Interleukin 2) • ITGAX (Integrin Subunit Alpha X) • TRB (T Cell Receptor Beta Locus)
    2d
    Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=20, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV
    3d
    CLL 2000: A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG (clinicaltrials.gov)
    P=N/A, N=2000, Not yet recruiting, German CLL Study Group | Initiation date: Aug 2025 --> Jan 2026
    Trial initiation date
    3d
    Clinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center. (PubMed, Adv Hematol)
    A subset of patients who were exposed to and were found to be relapsed, refractory, resistant, or intolerant to both BTKi and BCL2i-based regimens (n = 25) had high rates of progressive disease at first assessment (15.0%) and death (44.0%). These findings highlight an unmet clinical need for patients with CLL and underscore the urgency to develop effective new strategies to treat those patients who have already received covalent BTKi and BCL2i.
    Clinical data • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    4d
    ASSURE: Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients (clinicaltrials.gov)
    P3, N=552, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • IGH (Immunoglobulin Heavy Locus) • CD5 (CD5 Molecule) • FCER2 (Fc Fragment Of IgE Receptor II)
    |
    Chr del(17p) • Chr del(11q) • IGH mutation
    |
    Calquence (acalabrutinib)
    4d
    RETAIN: Retention Rate of Acalabrutinib in a Non-interventional Setting (clinicaltrials.gov)
    P=N/A, N=137, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=200 --> 137
    Enrollment closed • Enrollment change
    |
    Calquence (acalabrutinib)
    6d
    Systemic MIF facilitates chronic lymphocytic leukemia development independent of its cellular source. (PubMed, J Leukoc Biol)
    To identify the most relevant source of Mif in CLL, we generated two CLL mouse strains with B-lymphoid- or myeloid-lineage-specific Mif deletion. In contrast to the global Mif knockout, neither conditional Mif knockout significantly altered CLL progression, illustrating that the cellular source of Mif is less critical than its systemic presence in the tissue environment.
    Journal
    |
    MIF (Macrophage Migration Inhibitory Factor)
    7d
    Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 19 | Trial completion date: Mar 2043 --> Jul 2040 | Trial primary completion date: Mar 2027 --> Aug 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
    |
    ALK positive
    |
    cyclophosphamide • fludarabine IV • rimiducid (AP1903)